RhumbLine Advisers’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $43.2K | Buy |
600
+500
| +500% | +$28.5K | ﹤0.01% | 3613 |
|
|
2025
Q4 | $4.23K | Hold |
100
| – | – | ﹤0.01% | 3934 |
|
|
2025
Q3 | $5.69K | Buy |
+100
| New | +$3.31K | ﹤0.01% | 3904 |
|
|
2025
Q2 | – | Sell |
-14,784
| Closed | -$151K | – | 4218 |
|
|
2025
Q1 | $151K | Buy |
14,784
+2,796
| +23% | +$36.5K | ﹤0.01% | 3244 |
|
|
2024
Q4 | $167K | Sell |
11,988
-221
| -2% | -$3.9K | ﹤0.01% | 3285 |
|
|
2024
Q3 | $238K | Sell |
12,209
-132
| -1% | -$2.52K | ﹤0.01% | 3147 |
|
|
2024
Q2 | $230K | Buy |
12,341
+11,986
| +3,376% | +$253K | ﹤0.01% | 3144 |
|
|
2024
Q1 | $4.97K | Hold |
355
| – | – | ﹤0.01% | 3986 |
|
|
2023
Q4 | $3.01K | Hold |
355
| – | – | ﹤0.01% | 4055 |
|
|
2023
Q3 | $3.17K | Sell |
355
-581
| -62% | -$5.59K | ﹤0.01% | 4050 |
|
|
2023
Q2 | $8.07K | Sell |
936
-40,239
| -98% | -$429K | ﹤0.01% | 3992 |
|
|
2023
Q1 | $434K | Buy |
41,175
+2,716
| +7% | +$82.2K | ﹤0.01% | 2487 |
|
|
2022
Q4 | $1.3M | Buy |
38,459
+470
| +1% | +$22.7K | ﹤0.01% | 2012 |
|
|
2022
Q3 | $1.82M | Buy |
37,989
+1,106
| +3% | +$65.8K | ﹤0.01% | 1814 |
|
|
2022
Q2 | $2.1M | Buy |
36,883
+7,432
| +25% | +$469K | ﹤0.01% | 1738 |
|
|
2022
Q1 | $2.38M | Buy |
29,451
+606
| +2% | +$89.7K | ﹤0.01% | 1721 |
|
|
2021
Q4 | $5.85M | Sell |
28,845
-3,021
| -9% | -$655K | 0.01% | 1273 |
|
|
2021
Q3 | $8.59M | Sell |
31,866
-1,006
| -3% | -$242K | 0.01% | 1046 |
|
|
2021
Q2 | $8.46M | Sell |
32,872
-356
| -1% | -$98.5K | 0.01% | 1108 |
|
|
2021
Q1 | $9.97M | Buy |
33,228
+60
| +0.2% | +$18.7K | 0.01% | 991 |
|
|
2020
Q4 | $8.46M | Buy |
33,168
+1,282
| +4% | +$331K | 0.01% | 1035 |
|
|
2020
Q3 | $7.93M | Sell |
31,886
-746
| -2% | -$235K | 0.01% | 889 |
|
|
2020
Q2 | $11.3M | Buy |
32,632
+1,230
| +4% | +$384K | 0.02% | 711 |
|
|
2020
Q1 | $8.41M | Buy |
31,402
+2,195
| +8% | +$679K | 0.02% | 740 |
|
|
2019
Q4 | $9.46M | Buy |
29,207
+3,414
| +13% | +$990K | 0.02% | 868 |
|
|
2019
Q3 | $7.05M | Buy |
25,793
+3,050
| +13% | +$1.12M | 0.01% | 988 |
|
|
2019
Q2 | $12.1M | Sell |
22,743
-2,820
| -11% | -$1.41M | 0.02% | 678 |
|
|
2019
Q1 | $12.9M | Sell |
25,563
-960
| -4% | -$569K | 0.02% | 628 |
|
|
2018
Q4 | $13.1M | Buy |
26,523
+2,062
| +8% | +$1.24M | 0.03% | 579 |
|
|
2018
Q3 | $22.4M | Buy |
24,461
+29
| +0.1% | +$24.8K | 0.04% | 410 |
|
|
2018
Q2 | $17.9M | Buy |
24,432
+4,673
| +24% | +$5.39M | 0.04% | 474 |
|
|
2018
Q1 | $31.5M | Sell |
19,759
-4,879
| -20% | -$6.29M | 0.07% | 299 |
|
|
2017
Q4 | $22.1M | Buy |
24,638
+3,485
| +16% | +$2.06M | 0.04% | 415 |
|
|
2017
Q3 | $7.62M | Buy |
21,153
+560
| +3% | +$175K | 0.02% | 808 |
|
|
2017
Q2 | $6.04M | Buy |
20,593
+165
| +0.8% | +$47.7K | 0.01% | 896 |
|
|
2017
Q1 | $7.19M | Buy |
20,428
+5,733
| +39% | +$1.29M | 0.02% | 803 |
|
|
2016
Q4 | $2.71M | Buy |
14,695
+1,548
| +12% | +$315K | 0.01% | 1274 |
|
|
2016
Q3 | $3.39M | Buy |
13,147
+736
| +6% | +$190K | 0.01% | 1101 |
|
|
2016
Q2 | $2.65M | Buy |
12,411
+194
| +2% | +$43.4K | 0.01% | 1180 |
|
|
2016
Q1 | $2.52M | Buy |
12,217
+253
| +2% | +$48.6K | 0.01% | 1214 |
|
|
2015
Q4 | $3.02M | Buy |
11,964
+727
| +6% | +$149K | 0.01% | 1113 |
|
|
2015
Q3 | $1.85M | Buy |
11,237
+265
| +2% | +$46.9K | 0.01% | 1368 |
|
|
2015
Q2 | $2.06M | Sell |
10,972
-175
| -2% | -$30.1K | 0.01% | 1385 |
|
|
2015
Q1 | $1.84M | Buy |
11,147
+850
| +8% | +$175K | 0.01% | 1454 |
|
|
2014
Q4 | $2.39M | Buy |
10,297
+39
| +0.4% | +$8.34K | 0.01% | 1232 |
|
|
2014
Q3 | $1.86M | Sell |
10,258
-47
| -0.5% | -$8.99K | 0.01% | 1371 |
|
|
2014
Q2 | $1.98M | Buy |
10,305
+527
| +5% | +$93.2K | 0.01% | 1383 |
|
|
2014
Q1 | $1.78M | Sell |
9,778
-121
| -1% | -$23.9K | 0.01% | 1423 |
|
|
2013
Q4 | $1.69M | Sell |
9,899
-264
| -3% | -$42.6K | 0.01% | 1477 |
|
|
2013
Q3 | $1.59M | Sell |
10,163
-72
| -0.7% | -$13.3K | ﹤0.01% | 1480 |
|
|
2013
Q2 | $1.77M | Buy |
+10,235
| New | +$1.57M | 0.01% | 1388 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
RhumbLine Advisers's NKTR Position: Q1 2026 in Review
RhumbLine Advisers increased its Nektar Therapeutics (NKTR) stake by 500% in Q1 2026, buying an estimated $28.5K and bringing the position to 600 shares worth $43.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3613.
RhumbLine Advisers first reported a position in NKTR in Q2 2013 and has held it in 51 quarters since. The position peaked at $31.5M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- RhumbLine Advisers held 600 shares of Nektar Therapeutics worth $43.2K as of Q1 2026.
- RhumbLine Advisers bought 500 Nektar Therapeutics shares in Q1 2026, an estimated $28.5K.
- Nektar Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3613 holding.
- RhumbLine Advisers first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 51 quarters since.
- RhumbLine Advisers's Nektar Therapeutics position peaked at $31.5M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.